Literature DB >> 20626031

Anti-angiogenic therapy: adapting strategies to overcome resistant tumors.

Dianne C Mitchell1, Brad A Bryan.   

Abstract

Healthy cells, as well as benign and malignant tumors, depend upon the body's blood supply to bring in oxygen and nutrients and carry away waste products. Using this property against tumors, anti-angiogenic therapy targets the tumor vasculature with the aim of starving the tumor, and has demonstrated exceptional clinical efficacy against a number of tumors. This review discusses the current state of knowledge regarding anti-angiogenic therapies presently available to patients, and garners from both preclinical and clinical literature the benefits and side effects associated with anti-angiogenic therapies, the unfortunate mechanisms of acquired resistance to these novel therapeutics, and highlights promising next generation anti-angiogenics that may overcome the limitations encountered with first generation therapies.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20626031     DOI： 10.1002/jcb.22764

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN： 0730-2312            Impact factor:   4.429


  13 in total

1.  Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line.

Authors:  M Di Salvatore; A Orlandi; C Bagalà; M Quirino; A Cassano; A Astone; C Barone
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

Review 2.  BMPs and their clinical potentials.

Authors:  Meejung Kim; Senyon Choe
Journal:  BMB Rep       Date:  2011-10       Impact factor: 4.778

Review 3.  The role of semaphorins and their receptors in vascular development and cancer.

Authors:  Chenghua Gu; Enrico Giraudo
Journal:  Exp Cell Res       Date:  2013-02-17       Impact factor: 3.905

Review 4.  Targeting the metabolic microenvironment of tumors.

Authors:  Kate M Bailey; Jonathan W Wojtkowiak; Arig Ibrahim Hashim; Robert J Gillies
Journal:  Adv Pharmacol       Date:  2012

5.  A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.

Authors:  Sarina A Piha-Paul; Ecaterina E Dumbrava; Binoj C Nair; Wendy Xiong; Li Xu; Rosa Mostorino; Vivek Subbiah; Nizar Tannir; Siqing Fu; Aung Naing; Filip Janku; Daniel D Karp; Shreyaskumar Patel; Najat C Daw; David Hong; Funda Meric-Bernstam; Ralph Zinner
Journal:  Onco Targets Ther       Date:  2021-05-07       Impact factor: 4.147

6.  Dissociable roles for lateral orbitofrontal cortex and lateral prefrontal cortex during preference driven reversal learning.

Authors:  Adam Hampshire; Amir M Chaudhry; Adrian M Owen; Angela C Roberts
Journal:  Neuroimage       Date:  2011-10-30       Impact factor: 6.556

7.  Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.

Authors:  Monika Stimac; Tanja Dolinsek; Ursa Lampreht; Maja Cemazar; Gregor Sersa
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

8.  Dynamic Contrast Magnetic Resonance Imaging (DCE-MRI) and Diffusion Weighted MR Imaging (DWI) for Differentiation between Benign and Malignant Salivary Gland Tumors.

Authors:  S Assili; A Fathi Kazerooni; L Aghaghazvini; H R Saligheh Rad; J Pirayesh Islamian
Journal:  J Biomed Phys Eng       Date:  2015-12-01

9.  [The influence of inhibiting angiopoietin-2 on the biological characteristics of bronchogenic adenocarcinoma].

Authors:  Bailing Li; Guanxin Zhang; Xiaolei Hou; Yang Yuan; Xiaohong Liu; Dejun Gong; Shengdong Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-07

10.  Trans-3,4,5,4'-tetramethoxystilbene, a resveratrol analog, potently inhibits angiogenesis in vitro and in vivo.

Authors:  Liang-ke Chen; Peng-fei Qiang; Qi-ping Xu; Yi-hua Zhao; Fang Dai; Lu Zhang
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.